Oxazolidinone susceptibility patterns for 2005:: International report from the Zyvox® Annual Appraisal of Potency and Spectrum study

被引:30
作者
Ross, James E.
Fritsche, Thomas R.
Sader, Helio S.
Jones, Ronald N.
机构
[1] JMI Labs, N Liberty, IA 52317 USA
[2] Univ Fed Sao Paulo, Sao Paulo, Brazil
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
oxazolidinone; linezolid; resistance; MRSA; surveillance; non-USA;
D O I
10.1016/j.ijantimicag.2006.09.025
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The international (non-USA) ZAAPS Program has accumulated 4 years of linezolid resistance surveillance results tracking infections caused by organisms with evolving resistance profiles. The major organism groups monitored were: Staphylococcus aureus and coagulase-negative staphylococci (including methicillin [oxacill in] -resistant strains), enterococci (including vancomycin-resistant [VRE] strains), Streptococcus pneumoniae (including multidrug-resistant [MDR] strains), viridans group streptococci and P-haemolytic streptococci (4209 isolates overall). No linezolid-resistant strains were detected from the 16 monitored nations participating in 2005, consistent with previously reported 2002-2004 results. Linezolid remains highly active against Gram-positive strains including MRSA (MIC90, 2mg/L). With MDR in Gram-positive organisms increasing in prevalence, continued surveillance of linezolid appears to be prudent practice as linezolid becomes more widely prescribed for these difficult-to-treat infections. (c) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:295 / 301
页数:7
相关论文
共 22 条
[1]   Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program [J].
Anderegg, TR ;
Sader, HS ;
Fritsche, TR ;
Ross, JE ;
Jones, RN .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 (01) :13-21
[2]   A multicenter evaluation of linezolid antimicrobial activity in North America [J].
Ballow, CH ;
Jones, RN ;
Biedenbach, DJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 43 (01) :75-83
[3]   Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific [J].
Bell, JM ;
Turnidge, JD ;
Ballow, CH ;
Jones, RN .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (02) :339-345
[4]   Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program [J].
Birmingham, MC ;
Rayner, CR ;
Meagher, AK ;
Flavin, SM ;
Batts, DH ;
Schentag, JJ .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :159-168
[5]   Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe:: report from the Zyvox® antimicrobial potency study (ZAPS-Europe) [J].
Bolmstrom, A ;
Ballow, CH ;
Qwarnstrom, A ;
Biedenbach, DJ ;
Jones, RN .
CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (12) :791-800
[6]   Surveillance of linezolid resistance in Germany, 2001-2002 [J].
Brauers, J ;
Kresken, M ;
Hafner, D ;
Shah, PM .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (01) :39-46
[7]  
BRUINSMA NV, 2005, 16 EUR C CLIN MICR I
[8]   In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates [J].
Cercenado, E ;
García-Garrote, F ;
Bouza, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (01) :77-81
[9]  
*CLIN LAB STAND I, 2006, M100S16 CLSI
[10]  
Clinical and Laboratory Standards Institute, 2006, METH DIL ANT SUSC TE